Effect of GLP-1 receptor agonist treatment on body weight in obese antipsychotic-treated patients with schizophrenia: a randomized, placebo-controlled trial

详细信息    查看全文

• 作者：Pelle L. Ishø ; y ; Filip K. Knop ; Brian V. Broberg ; Nikolaj Bak ; Ulrik B. Andersen ; Niklas R. Jø ; rgensen ; Jens J. Holst ; Birte Y. Glenthø ; j and Bjø ; rn H. Ebdrup
• 刊名：Diabetes, Obesity and Metabolism
• 出版年：2017
• 出版时间：February 2017
• 年：2017
• 卷：19
• 期：2
• 页码：162-171
• 全文大小：801K
• ISSN：1463-1326

文摘

Schizophrenia is associated with cardiovascular co-morbidity and a reduced life-expectancy of up to 20 years. Antipsychotics are dopamine D₂ receptor antagonists and are the standard of medical care in schizophrenia, but the drugs are associated with severe metabolic side effects such as obesity and diabetes. Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are registered for treatment of both obesity and type 2 diabetes. We investigated metabolic effects of the GLP-1RA, exenatide once-weekly, in non-diabetic, antipsychotic-treated, obese patients with schizophrenia.